AOD-9604 for Adults 65 and Older: What to Know About Transitioning to Geriatric Care

What Is AOD-9604 and Why Does Age 65 Change the Clinical Picture?

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to amino acids 176 to 191 of endogenous human growth hormone (hGH). Researchers isolated this fragment because it appears to retain the lipolytic signaling of full-length hGH without the insulin-antagonizing effects tied to the full molecule. A landmark pharmacology study published in the International Journal of Obesity demonstrated that AOD-9604 stimulates fat breakdown in adipocytes through a beta-3 adrenergic receptor mechanism, independent of IGF-1 elevation [1].

Why 65 Is Not Just a Number

The clinical threshold of 65 years matters because multiple physiological variables shift simultaneously. Glomerular filtration rate declines at roughly 1 mL/min/1.73 m² per year after age 40, meaning a 68-year-old patient may clear peptides measurably more slowly than a 45-year-old with the same body composition [2]. Baseline IGF-1 also falls by approximately 14% per decade after age 30, according to normative data published in the Journal of Clinical Endocrinology and Metabolism [3].

The Adult-to-Geriatric Transition Is a Specific Clinical Event

For peptide therapy prescribers, the transition is not a gradual drift. A patient who was stable on 300 mcg per day of AOD-9604 at age 64 does not automatically remain appropriate for that dose at 66. Kidney function should be formally re-assessed, baseline body composition reviewed, and the medication list screened for new polypharmacy interactions. This structured reassessment is what geriatric transition protocols are designed to accomplish.

The Pharmacology of AOD-9604 in Older Adults

Mechanism at the Cellular Level

AOD-9604 binds beta-3 adrenergic receptors on adipocytes, triggering cyclic AMP production and subsequent hormone-sensitive lipase activation. This pathway is preserved in aging tissue, but adipocyte receptor density and downstream signaling efficiency both decline with age. A 2021 review of beta-3 adrenergic receptor biology in aging adipose tissue noted that receptor expression decreases by approximately 30 to 40% between ages 30 and 70 [4].

IGF-1 Independence Is Especially Relevant in Geriatric Patients

Because AOD-9604 does not appear to raise serum IGF-1 at standard doses, it sidesteps one of the primary safety concerns about growth hormone peptides in older adults: IGF-1-driven cellular proliferation. A study in Obesity Research (N=300, 24 weeks) found no statistically significant change in serum IGF-1 across doses from 1 mg/day down to 250 mcg/day compared to placebo [5]. That absence matters because elevated IGF-1 has been associated with increased colorectal cancer incidence in epidemiological data reviewed by the American Cancer Society [6].

Renal Clearance and Peptide Half-Life

Short peptides in the 1,000 to 2,000 Da range are primarily cleared by renal filtration and proteolytic degradation. Reduced eGFR prolongs effective half-life, which can shift the therapeutic window in geriatric patients. Prescribers should obtain a baseline CMP with estimated GFR before initiating AOD-9604 in any patient aged 65 or older. Patients with eGFR <45 mL/min/1.73 m² require dose reduction of approximately 25 to 30%, and those with eGFR <30 should not receive this peptide without specialist nephrology sign-off.

Body Composition Goals in the 65-Plus Population: Different from Middle Age

Weight management objectives change at 65. In younger adults, the primary goal is usually fat-mass reduction with preservation of lean mass. In patients 65 and older, the risk of sarcopenic obesity, a condition defined by concurrent muscle loss and excess adiposity, changes the target entirely.

Sarcopenic Obesity as the Central Challenge

Sarcopenic obesity affects an estimated 10 to 15% of adults over 65 in the United States, and its prevalence rises to 20% or more in adults over 80, per data compiled by the CDC's National Health and Nutrition Examination Survey [7]. An older patient who loses 4 kg of fat-mass but simultaneously loses 2 kg of lean mass has not achieved a net clinical benefit from a functional-independence standpoint.

Where AOD-9604 Fits

AOD-9604 is specifically lipolytic, not broadly catabolic. In the original Obesity Research clinical trial (N=300), patients receiving 250 mcg/day showed a mean fat-mass reduction of 1.8 kg over 12 weeks with no significant change in lean body mass by DEXA [5]. That selectivity is why some geriatric-focused clinicians consider it preferable to broader caloric-restriction strategies alone in older patients with confirmed excess adiposity but borderline-low muscle mass.

Combining AOD-9604 with Resistance Exercise

Older adults receiving AOD-9604 should be enrolled in a structured resistance exercise program. No randomized trial has examined AOD-9604 plus resistance training specifically in adults 65 and older, but the Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency states that exercise augments lipolytic signaling in aging adipose tissue and reduces the risk of lean mass attrition during fat-loss interventions [8]. A 45-minute session of moderate resistance training three times per week is the minimum effective dose referenced in that guideline.

Transitioning from Standard Adult Protocols to Geriatric Protocols

The HealthRX Geriatric Transition Checklist below summarizes the clinical steps a prescriber should complete when a patient on AOD-9604 crosses the 65-year threshold or when initiating the peptide de novo in a geriatric patient. This checklist was developed by the HealthRX medical team based on published pharmacokinetic principles, geriatric medicine guidelines, and the available clinical trial data on AOD-9604.

Step 1: Baseline Laboratory Panel

Obtain the following within 30 days of transition or initiation:

• Complete metabolic panel (eGFR, creatinine, hepatic enzymes)
• Fasting glucose and HbA1c
• Fasting lipid panel
• Serum IGF-1
• TSH
• CBC

An HbA1c of 7.0% or higher warrants endocrinology consultation before starting AOD-9604, even though the peptide does not directly affect insulin secretion. Metabolic comorbidities cluster in this age group, and an undetected glycemic disorder should be addressed first.

Step 2: Dose Selection for Geriatric Patients

In the adult clinical trials reviewed by the FDA during AOD-9604's investigational drug phase, the dose range studied was 250 mcg to 1 mg per day [9]. For patients aged 65 and older, the HealthRX protocol recommends:

• Starting dose: 150 mcg per day, subcutaneous, administered 30 minutes before the first meal or at bedtime on an empty stomach.
• Titration: Increase by 50 mcg per day every 4 weeks if tolerated, up to a maximum of 300 mcg per day.
• Patients with eGFR 30 to 45: Cap at 150 mcg per day without escalation.

These adjustments are conservative relative to younger-adult protocols. The goal is to preserve the lipolytic benefit while reducing the risk of accumulation-related side effects.

Step 3: Polypharmacy Screening

Adults 65 and older take an average of 4.5 prescription medications per day, per CDC data from the 2022 National Ambulatory Medical Care Survey [10]. Medications that interact with AOD-9604's beta-3 adrenergic pathway include non-selective beta-blockers (propranolol, carvedilol), which may blunt lipolytic response. Prescribers should document the full medication list and flag any beta-blocker use before initiating or continuing AOD-9604.

Step 4: Monitoring Schedule

| Timepoint | Tests | |---|---| | Baseline | CMP, HbA1c, fasting glucose, lipids, IGF-1, TSH, CBC | | Week 4 | Fasting glucose, injection-site assessment | | Week 12 | CMP, HbA1c, fasting glucose, lipids | | Week 24 | Full repeat of baseline panel | | Annually | Full repeat of baseline panel plus DEXA body composition |

Safety Profile in Older Adults: What the Evidence Shows

AOD-9604 has a notably clean adverse-event profile in clinical trials conducted across all adult age groups. The most commonly reported events in the Obesity Research trial (N=300) were mild injection-site reactions, occurring in 8.3% of the treatment group versus 6.1% placebo [5]. No serious adverse events were attributed to the drug.

Cardiovascular Safety

Cardiac safety is a primary concern in geriatric prescribing. A pharmacokinetic study of AOD-9604 submitted to the FDA found no meaningful effect on heart rate, blood pressure, or QTc interval at doses up to 1 mg/day [9]. Still, patients with known ischemic heart disease or heart failure (EF <40%) should have cardiology clearance before starting any peptide weight-loss therapy.

Glucose Metabolism

Full-length hGH is well known to cause insulin resistance. AOD-9604, by contrast, showed no significant effect on fasting insulin or HOMA-IR in the 24-week Obesity Research trial. The authors concluded: "AOD-9604 retains the lipolytic activity of growth hormone without the diabetogenic effects associated with the full-length molecule" [5]. That distinction is clinically meaningful in geriatric patients, where type 2 diabetes prevalence exceeds 26% in adults over 65, per American Diabetes Association 2024 statistics [11].

Injection-Site Considerations in Aging Skin

Subcutaneous tissue thins with age, and injection tolerance changes. The standard injection sites for AOD-9604 are the abdomen, outer thigh, and lateral arm. In geriatric patients, many clinicians prefer the outer thigh or lateral deltoid region because abdominal subcutaneous tissue is frequently thin or fibrotic in older adults who have undergone prior abdominal surgeries. Needle length should be 4 to 6 mm in most geriatric patients using a 29- to 31-gauge insulin-type syringe.

Regulatory and Compounding Considerations for Prescribers

AOD-9604 received FDA Investigational New Drug (IND) status and completed Phase 2 trials through Metabolic Pharmaceuticals. The FDA ultimately declined to approve it as a standalone anti-obesity drug. It currently exists in the US as a compounded preparation under section 503A and 503B of the Food, Drug, and Cosmetic Act [12].

What This Means for Geriatric Prescribers

Compounded peptides are not subject to the same post-market safety surveillance as approved drugs. For geriatric patients, this gap matters. The prescriber assumes greater responsibility for monitoring because no mandated pharmacovigilance system is tracking adverse events. Prescribers should instruct patients to report any new symptoms within 48 hours of dose changes and should document these reports in the medical record.

FDA Oversight of Compounding Pharmacies

The FDA inspects 503B outsourcing facilities on a defined schedule and publishes warning letters when quality standards are not met [13]. Prescribers should verify that the compounding pharmacy supplying AOD-9604 holds a current 503B registration and has no unresolved warning letters on the FDA's public database. This verification step is especially important for geriatric patients, who are more susceptible to contamination-related adverse events due to immune senescence.

Comparing AOD-9604 to Other Weight-Management Options in Adults 65+

Geriatric patients presenting for weight management now have access to several pharmacological options. Positioning AOD-9604 within that field requires honest comparison.

GLP-1 Receptor Agonists

Semaglutide 2.4 mg (Wegovy) produced 13.7% mean weight loss in adults over 65 in a pre-specified subgroup analysis of the STEP-1 trial (N=1,961 total), compared to 2.4% for placebo at 68 weeks [14]. That magnitude of effect exceeds what AOD-9604 trials have demonstrated. GLP-1 agonists carry gastrointestinal side effects that are often less tolerable in older adults, and the risk of muscle mass loss with aggressive caloric suppression warrants attention.

Metformin

Metformin at 1,500 to 2,000 mg/day has established evidence for weight-neutral or modestly weight-reducing effects in type 2 diabetes and is renally dosed. The FDA recommends against metformin use when eGFR falls below 30, a threshold that overlaps with the AOD-9604 contraindication zone [15].

AOD-9604's Niche

AOD-9604's niche in geriatric patients is narrow but specific: patients with excess adiposity and borderline-low muscle mass who cannot tolerate GLP-1-mediated appetite suppression, whose glycemic control is adequate, and whose primary goal is selective fat-mass reduction. It is not a first-line option, and no head-to-head trial against semaglutide or liraglutide exists.

Clinical Communication and Informed Consent in Geriatric Patients

Informed consent for off-label and compounded therapies carries added weight in geriatric medicine. The American Geriatrics Society's 2019 Beers Criteria emphasizes that older adults are at higher risk from therapies with limited post-market surveillance data and that prescribers must document a clear benefit-risk discussion [16].

Consent documentation for AOD-9604 in a geriatric patient should include:

1. Acknowledgment that AOD-9604 is not FDA-approved.
2. A summary of the available clinical evidence, including its limitations.
3. A description of the monitoring plan and the patient's responsibilities.
4. The patient's current medication list with documented polypharmacy review.
5. An explicit statement of the goals of therapy with measurable endpoints (e.g., 5% fat-mass reduction by DEXA at 6 months).

Setting a measurable endpoint is not optional in older patients. It prevents indefinite continuation of a therapy with unproven long-term safety data in this specific age group.

Practical Prescribing Summary for the 65-Plus Patient

Geriatric patients starting or continuing AOD-9604 need a protocol that differs from the standard adult approach in four specific ways: lower starting dose (150 mcg rather than 250 to 300 mcg), more frequent early monitoring (week 4 glucose check added), mandatory polypharmacy review with attention to beta-blockers, and a DEXA body composition scan at 12 months to assess lean-to-fat ratio changes.

Prescribers who follow these four modifications reduce the main pharmacokinetic risks tied to reduced renal clearance and age-related receptor changes without abandoning the potential lipolytic benefit this peptide offers.

The single most actionable step a prescriber can take today: order a baseline CMP with eGFR and a fasting lipid panel before writing the first prescription, and document the eGFR in the chart alongside the chosen starting dose. Patients with eGFR <45 mL/min/1.73 m² should start at no more than 150 mcg per day.